Caesars Entertainment misses Q2 earnings expectations, shares edge lower
Investing.com - Mizuho (NYSE:MFG) raised its price target on Establishment Labs Inc. (NASDAQ:ESTA) to $70.00 from $58.00 on Thursday, maintaining an Outperform rating on the stock. The new target represents an 87% upside from the current price of $37.50. According to InvestingPro data, analysts maintain a strong buy consensus with targets ranging from $38 to $62.
The price target increase follows Mizuho’s assessment that the company’s Motiva breast implant product is successfully transforming the U.S. breast augmentation market since receiving FDA approval nine months ago.
Mizuho based its updated outlook on discussions with key opinion leader Dr. Jerry Chidester, who provided insights on second-quarter 2025 aesthetic procedure trends and manufacturer preferences in his practice.
The firm noted that despite pricing and bundling strategies from competitors, practices are showing preference for Motiva, with its real-world safety profile demonstrating similar strength to clinical trial results.
Mizuho expressed bullishness on the medium-term outlook for Motiva in the U.S. market, citing early success in gaining market share in high-volume practices and potential for the company’s Preservé and MIA products.
In other recent news, Establishment Labs Holdings Inc . has reaffirmed its 2025 financial guidance, indicating that its second-quarter U.S. revenue is likely to surpass consensus estimates. The company also noted no slowdown in international markets, which was discussed during its investor day. BTIG analysts have initiated coverage of Establishment Labs with a Buy rating and a price target of $62, highlighting the potential of the company’s Motiva breast implants. Needham has upgraded the stock from Hold to Buy, setting a $48 price target, citing easing trade tensions and the company’s growth potential in international markets.
Additionally, Establishment Labs reported a 91% sequential increase in U.S. sales for the first quarter of 2025, surpassing consensus estimates. The company’s gross margin improved by 160 basis points year-over-year, though its adjusted EBITDA margin declined due to increased expenditures for the U.S. market launch. In leadership news, Establishment Labs appointed Peter Caldini as the new CEO, effective immediately, following his interim role since March 1. Caldini’s extensive experience in healthcare and consumer companies is expected to help drive the company toward its financial goals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.